Discussing three recent publications:
1. Updated results of Keynote-426 (https://doi.org/10.1016/S1470-2045(20)30436-8)
2. Ph+ ALL tx with dasatinib/prednisone --> blinatumomab (https://www.nejm.org/doi/full/10.1056/NEJMoa2016272)
3. Decitabine + G-CSF to prevent AML relapse following alloHSCT (https://ascopubs.org/doi/pdf/10.1200/JCO.19.03277)
